Cyclin-dependent kinase 19 upregulation correlates with an unfavorable prognosis in hepatocellular carcinoma
BMC Gastroenterology — Cai X, Deng J, Zhou J, et al. | October 19, 2021
In hepatocellular cancer (HCC), cyclin-dependent kinase 19 (CDK19) may serve as a prognostic marker but further exploration of its therapeutic potential is required.
The potential roles of CDK19 in HCC were investigated by using public databases and wet-bench hepatic cell line experiments.
HCC tissues, vs normal liver tissues, exhibited marked CDK19 upregulation, and a high diagnostic value of CDK19 mRNA expression was evident in HCC patients.
In cases with stage 2–3, stage 3–4, and grade 2 disease, CDK19 upregulation holds significant prognostic value for overall survival.
Eight of the 10 genes with correlation to CDK19 were found to have excellent prognostic value in HCC.
Direct involvement of these hub genes in cell division and regulation of the G2/M cell cycle transition was seen.
A high probability of the involvement of CDK19 in several cellular functions, such as proliferation, migration, and invasion is suggested by protein–protein interaction and pathway predictions.
Read the full article on BMC Gastroenterology